Palisade Bio Balance Sheet Health
Financial Health criteria checks 6/6
Palisade Bio has a total shareholder equity of $6.6M and total debt of $235.0K, which brings its debt-to-equity ratio to 3.6%. Its total assets and total liabilities are $9.3M and $2.7M respectively.
Key information
3.6%
Debt to equity ratio
US$235.00k
Debt
| Interest coverage ratio | n/a |
| Cash | US$8.05m |
| Equity | US$6.61m |
| Total liabilities | US$2.73m |
| Total assets | US$9.34m |
Recent financial health updates
Recent updates
Palisade Bio announces CEO transition
Oct 11Palisade Bio streamlines operations, including cutting 20% of employees
Sep 15Palisade Bio GAAP EPS of -$0.12
Aug 15Palisade Bio begins phase 3 study testing LB1148 for postoperative return of bowel function
Jul 27Palisade Bio rises 10% after starting phase 3 study of gastrointestinal surgery therapy
Jun 29Palisade Bio (NASDAQ:PALI) Will Have To Spend Its Cash Wisely
Mar 28
Palisade Bio: Guarding Intestinal Integrity
Nov 07Financial Position Analysis
Short Term Liabilities: PALI's short term assets ($8.9M) exceed its short term liabilities ($2.7M).
Long Term Liabilities: PALI's short term assets ($8.9M) exceed its long term liabilities ($47.0K).
Debt to Equity History and Analysis
Debt Level: PALI has more cash than its total debt.
Reducing Debt: PALI had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PALI has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: PALI is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.